• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

HHS to dis­trib­ute 1.6M mon­key­pox vac­cine dos­es this year

3 years ago
Pharma

No­vo Nordisk spells out the de­tails be­hind a PhII NASH fail­ure which re­shaped its clin­i­cal plans

3 years ago
R&D

Am­gen sells its Turk­ish man­u­fac­tur­ing arm for $135M

3 years ago
Deals
Manufacturing

Vedan­ta opens man­u­fac­tur­ing fa­cil­i­ty to pro­duce lead can­di­date as it heads for PhI­II

3 years ago
Pharma
Manufacturing

US spends $275M more on Eli Lil­ly's Covid mAb as about half of sup­plies have been ad­min­is­tered so far

3 years ago
Coronavirus

Eu­ro­pean Com­mis­sion says it does­n't have texts be­tween pres­i­dent Ur­su­la von der Leyen and Pfiz­er CEO Al­bert Bourla

3 years ago
Pharma
Coronavirus

Sid Mukher­jee, Lew Cant­ley be­hind new can­cer biotech with food+drug com­bo treat­ment am­bi­tions 

3 years ago
People
Financing

Fac­ing set­backs for months and an ac­tivist at­tack, Cat­a­lyst Bio­sciences pre­pares to call it quits

3 years ago
R&D

Feel­ing the heat of the bear mar­ket, eye dis­ease biotech to im­ple­ment 'ex­pense stream­lin­ing' plan and lay off 50

3 years ago
People
Pharma

San­ther­a's clin­i­cal da­ta are in, but NDA de­layed 4-6 months by third par­ty man­u­fac­tur­er

3 years ago
R&D

With da­ta to pro­pel it in­to PhI­II, 89bio asks mar­ket for near­ly $100M to bankroll ex-Te­va drug

3 years ago
Financing
R&D

Con­struc­tion un­der­way for new life sci­ence cen­ter to ac­com­mo­date Seat­tle's grow­ing life sci­ence sec­tor

3 years ago
R&D

FDA's VRB­PAC votes in fa­vor of adapt­ing the Covid-19 vac­cine to the lat­est Omi­cron vari­ant

3 years ago
FDA+
Coronavirus

Up­dat­ed: As bear mar­ket con­tin­ues to beat down biotech, ARCH clos­es a $3B ear­ly-stage fund

3 years ago
People
Financing

Astel­las sub­sidiary to part­ner with Pitts­burgh up­start in search for 'un­drug­gable' pro­teins

3 years ago
Deals
R&D

Reel­ing from Covid flop, Icosavax says its RSV can­di­date passed ear­ly test. But in­vestors need some more con­vinc­ing

3 years ago
R&D

Sanofi to cut in­sulin prices for unin­sured from $99 to $35, match­ing the in­sulin cap com­ing through Con­gress

3 years ago
Pharma

Pfiz­er, Sanofi-backed LNP out­fit goes back to the well and draws $120M for its trek to the clin­ic

3 years ago
Financing

Ox­ford spin­out nabs al­most $100M in new cash to test PD-1 in au­toim­mune dis­eases and hunt for a CEO

3 years ago
Financing
Startups

Up­dat­ed: Some phar­ma com­pa­nies promise to cov­er abor­tion-re­lat­ed trav­el costs — while oth­ers won't go that far yet

3 years ago
Pharma

Au­robindo Phar­ma re­ceives warn­ing let­ter from In­di­a's SEC fol­low­ing more FDA ques­tion marks

3 years ago
Pharma
FDA+

Ax­some's long de­layed de­pres­sion drug is back up for la­bel dis­cus­sions at the FDA, trig­ger­ing a big spike in the ...

3 years ago
FDA+

Basilea toss­es an on­col­o­gy drug back to Mer­ck, dou­bling down on an­tibi­otics in re­vamp

3 years ago
Deals
R&D

Charles Riv­er Lab­o­ra­to­ries to start cell and gene ther­a­py man­u­fac­tur­ing at UK site in Sep­tem­ber

3 years ago
Manufacturing
First page Previous page 505506507508509510511 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times